Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro1

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,736

The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death

Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,909

The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene

Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789

Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6

Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440

SRα Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat

Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., & Arai, N. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.1.466-472.1988 · Cited by 1,330

A novel domain within the 55 kd TNF receptor signals cell death

Tartaglia, L. A., Ayres, T. M., Wong, G. H., & Goeddel, D. V. (1993) · Cell · doi:10.1016/0092-8674(93)90464-2 · Cited by 1,290

Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule

Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., & Mountz, J. D. (1994) · Science · doi:10.1126/science.7510905 · Cited by 1,108

Modulation of Osteoclast Differentiation

Suda, T., Takahashi, N., & Martin, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004

OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION

Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-123-5-2600 · Cited by 934

A novel molecular mechanism modulating osteoclast differentiation and function

Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S.-I., Tsuda, E., Morinaga, T., Udagawa, N., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00121-0 · Cited by 264

Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone

Clines, G. A., & Guise, T. A. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00543 · Cited by 255

Pathogenesis of bone erosions in rheumatoid arthritis

Goldring, S. R., & Gravallese, E. M. (2000) · Current Opinion in Rheumatology · doi:10.1097/00002281-200005000-00006 · Cited by 243

Vitamin D and bone

Suda, T., Ueno, Y., Fujii, K., & Shinki, T. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10331 · Cited by 248

Osteoclast Differentiation Factor Mediates an Essential Signal for Bone Resorption Induced by 1α,25-Dihydroxyvitamin D3, Prostaglandin E2, or Parathyroid Hormone in the Microenvironment of Bone

Tsukii, K., Shima, N., Mochizuki, S.-I., Yamaguchi, K., Kinosaki, M., Yano, K., Shibata, O., Udagawa, N., Yasuda, H., Suda, T., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8610 · Cited by 237

Discovery of the RANKL/RANK/OPG system

Yasuda, H. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01175-1 · Cited by 251

Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status

Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., & Delmas, P. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7657 · Cited by 250

Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts

Wright, L. M., Maloney, W. J., YU, X., Kindle, L., Collin‐Osdoby, P., & Osdoby, P. (2005) · Bone · doi:10.1016/j.bone.2005.01.021 · Cited by 232

TRANCE is a TNF family member that regulates dendritic cell and osteoclast function

Wong, B. R., Josien, R., & Choi, Y. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.6.715 · Cited by 230

Proinflammatory cytokine (TNFα/IL‐1α) induction of human osteoclast formation

Kudo, O., Fujikawa, Y., Itonaga, I., Sabokbar, A., Torisu, T., & Athanasou, N. (2002) · Journal of Pathology · doi:10.1002/path.1190 · Cited by 193

Genetic control of skeletal development

Wagner, E. F., & Karsenty, G. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00228-8 · Cited by 229

A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype

Cundy, T. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.18.2119 · Cited by 228

IL-1 plays an important role in the bone metabolism under physiological conditions

Lee, Y.-M., Fujikado, N., Manaka, H., Yasuda, H., & Iwakura, Y. (2010) · International Immunology · doi:10.1093/intimm/dxq431 · Cited by 226

A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis

Eswarakumar, V. P., Horowitz, M. C., Locklin, R. M., Morriss‐Kay, G. M., & Lonai, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405031101 · Cited by 224

Regulatory Effects and Interactions of the Wnt and OPG-RANKL-RANK Signaling at the Bone-Cartilage Interface in Osteoarthritis

Kovács, B., Vajda, E., & Nagy, E. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184653 · Cited by 224

Estrogen Inhibits Vascular Calcification via Vascular RANKL System

Osako, M. K., Hironori Nakagami, A., Koibuchi, N., Shimizu, H., Nakagami, F., Koriyama, H., Shimamura, M., Miyake, T., Rakugi, H., & Morishita, R. (2010) · Circulation Research · doi:10.1161/circresaha.110.216846 · Cited by 222

Pathogenesis of Age-Related Bone Loss in Humans

Khosla, S. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls163 · Cited by 222

Role of RANKL and RANK in bone loss and arthritis

Jones, D. H., Kong, Y.-Y., & Penninger, J. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii32 · Cited by 225

Bone Morphogenetic Protein 2 Stimulates Osteoclast Differentiation and Survival Supported by Receptor Activator of Nuclear Factor-κB Ligand

Itoh, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., Higashio, K., Quinn, J. M. W., Gillespie, M. T., Martin, T. J., et al. (2001) · Endocrinology · doi:10.1210/endo.142.8.8300 · Cited by 250

Osteoimmunology: Crosstalk Between the Immune and Bone Systems

Nakashima, T., & Takayanagi, H. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9316-6 · Cited by 218

Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands

HOROWITZ, M., Xi, Y., WILSON, K., & Kacena, M. A. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00030-7 · Cited by 215

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (Review)

Liu, W. X., & Zhang, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3152 · Cited by 223

Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment

Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215

Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus*

Ikeda, T., Kasai, M., Utsuyama, M., & Hirokawa, K. (2001) · Endocrinology · doi:10.1210/endo.142.4.8070 · Cited by 215

Interleukin-10 Inhibits Bone Resorption: A Potential Therapeutic Strategy in Periodontitis and Other Bone Loss Diseases

Zhang, Q., Chen, B., Yan, F., Guo, J., Zhu, X., Ma, S., & Yang, W. R. (2014) · BioMed Research International · doi:10.1155/2014/284836 · Cited by 223

Oral Inflammatory Diseases and Systemic Inflammation: Role of the Macrophage

Hastürk, H., Kantarcı, A., & Dyke, T. E. V. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00118 · Cited by 215

Adrenergic regulation of bone metabolism: Possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells

Togari, A. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10121 · Cited by 211

Interaction between osteoblast and osteoclast: impact in bone disease.

Phan, T. C. A., Xu, J., & Zheng, M. (2004) · PubMed · doi:10.14670/hh-19.1325 · Cited by 213

Osteopontin Facilitates Angiogenesis, Accumulation of Osteoclasts, and Resorption in Ectopic Bone

Asou, Y., Rittling, S. R., Yoshitake, H., Tsuji, K., Shinomiya, K., Nifuji, A., Denhardt, D. T., & Noda, M. (2001) · Endocrinology · doi:10.1210/endo.142.3.8006 · Cited by 205

Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia

Kawaguchi, H., Manabe, N., Miyaura, C., Chikuda, H., Nakamura, K., & Kuro‐o, M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5705 · Cited by 204

Bone Aging, Cellular Senescence, and Osteoporosis

Pignolo, R. J., Law, S. F., & Chandra, A. (2021) · JBMR Plus · doi:10.1002/jbm4.10488 · Cited by 217

Molecular mechanisms and clinical management of cancer bone metastasis

Wang, M., Xia, F., Wei, Y., & Wei, X. (2020) · Bone Research · doi:10.1038/s41413-020-00105-1 · Cited by 204

Bortezomib inhibits human osteoclastogenesis

von Metzler, I., Krebbel, H., Hecht, M., Manz, R., Fleissner, C., Mieth, M., Kaiser, M., Jakob, C., Sterz, J., Kleeberg, L., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404806 · Cited by 197

Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone

Keller, E. T., Zhang, J., Cooper, C. R., Smith, P. C., McCauley, L. K., Pienta, K. J., & Taichman, R. S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1015599831232 · Cited by 200

Aging Increases Stromal/Osteoblastic Cell-Induced Osteoclastogenesis and Alters the Osteoclast Precursor Pool in the Mouse

Cao, J., Wronski, T. J., Iwaniec, U. T., Phleger, L., Kurimoto, P., Boudignon, B. M., & Halloran, B. P. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050503 · Cited by 197

Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells

Murakami, T., Yamamoto, M., Yamamoto, M., Ono, K., Nishikawa, M., Nagata, N., Motoyoshi, K., & Akatsu, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9723 · Cited by 195

17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α.

Saika, M., Inoue, D., Kido, S., & Matsumoto, T. (2001) · Endocrinology · doi:10.1210/endo.142.6.8220 · Cited by 194

Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures

Langdahl, B. L., Carstens, M., Stenkjær, L. L., & Eriksen, E. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1245 · Cited by 190

Effect of Estrogen versus Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men

Khosla, S., Atkinson, E. J., Dunstan, C. R., & O’Fallon, W. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8397 · Cited by 191

Demographic variations in the rising incidence of esophageal adenocarcinoma in white males

Bollschweiler, E., Wolfgarten, E., Gutschow, C. A., & H�lscher, A. H. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 452

The proliferation and phenotypic expression of human osteoblasts on tantalum metal

Findlay, D. M., Welldon, K. J., Atkins, G. J., Howie, D. W., Zannettino, A. C. W., & Bobyn, D. J. (2003) · Biomaterials · doi:10.1016/j.biomaterials.2003.09.005 · Cited by 189

Osteoclasts are important for bone angiogenesis

Cackowski, F. C., Anderson, J. L., Patrene, K. D., Choksi, R. J., Shapiro, S. D., Windle, J. J., Blair, H. C., & Roodman, G. D. (2010) · Blood · doi:10.1182/blood-2009-08-237628 · Cited by 188

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.

Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187

Serum levels of osteoprotegerin increase with age in a healthy adult population.

Kudlacek, S., Schneider, B., Woloszczuk, W., Pietschmann, P., & Willvonseder, R. (2003) · Bone · doi:10.1016/s8756-3282(03)00090-5 · Cited by 187

The RANK/RANKL/OPG triad in cancer-induced bone diseases

Dougall, W. C., & Chaisson, M. L. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9021-3 · Cited by 189

Osteocyte regulation of bone mineral: a little give and take

Atkins, G. J., & Findlay, D. M. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1915-z · Cited by 194

Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.

Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1047 · Cited by 186

The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis

Haynes, D. R., Crotti, T. N., Potter, A. E., Loric, M., Atkins, G. J., Howie, D. W., & Findlay, D. M. (2001) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.83b6.10905 · Cited by 186

Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts

Thomas, G. P., Baker, S., Eisman, J. A., & Gardiner, E. M. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1700451 · Cited by 184

Evaluation of Pharmaceuticals With a Novel 50-Hour Animal Model of Bone Loss

Tomimori, Y., Mori, K., Koide, M., Nakamichi, Y., Ninomiya, T., Udagawa, N., & Yasuda, H. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090217 · Cited by 184

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180

Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF

Fujita, K.-I., & Janz, S. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-71 · Cited by 179

Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics

VAANANEN, K. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.018 · Cited by 176

Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.

Cao, J., Venton, L., Sakata, T., & Halloran, B. P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.270 · Cited by 173

Is Inflammation a Friend or Foe for Orthodontic Treatment?: Inflammation in Orthodontically Induced Inflammatory Root Resorption and Accelerating Tooth Movement

Yamaguchi, M., & Fukasawa, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052388 · Cited by 175

The RANKL-RANK Story

Nagy, V., & Penninger, J. M. (2015) · Gerontology · doi:10.1159/000371845 · Cited by 175

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

Baud’huin, M., Lamoureux, F., Duplomb, L., Rédiní, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 177

Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure

Kazama, J. J., Shigematsu, T., Yano, K., Tsuda, E., Miura, M., Iwasaki, Y., Kawaguchi, Y., Gejyo, F., Kurokawa, K., & Fukagawa, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.31402 · Cited by 169

Role of RANKL–RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications

Kohli, S. S., & Kohli, V. S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83401 · Cited by 181

The Role of Receptor Activator of Nuclear Factor- B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases

Hofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 178

Low-Dose Creatine Combined with Protein during Resistance Training in Older Men

CANDOW, D. G., LITTLE, J. P., CHILIBECK, P. D., ABEYSEKARA, S., ZELLO, G. A., KAZACHKOV, M., CORNISH, S. M., & YU, P. H. (2008) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e318176b310 · Cited by 168

Osteotropic cancers: From primary tumor to bone

Buijs, J. T., & van der Pluijm, G. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.05.044 · Cited by 175

Recent advances in osteoclast biology and pathological bone resorption.

Blair, H. C., & Athanasou, N. A. (2004) · PubMed · doi:10.14670/hh-19.189 · Cited by 169

Disruption of BMP Signaling in Osteoblasts Through Type IA Receptor (BMPRIA) Increases Bone Mass

Kamiya, N., Ye, L., Kobayashi, T., Lucas, D. J., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q., & Mishina, Y. M. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080809 · Cited by 167

Osteoprotegerin (OPG) is localized to the Weibel‐Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor

Zannettino, A. C. W., Holding, C. A., Diamond, P., Atkins, G. J., Kostakis, P., Farrugia, A., Gamble, J. R., To, L. B., Findlay, D. M., & Haynes, D. R. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20354 · Cited by 169

Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro

Lin, D., Tarnowski, C. P., Zhang, J., Dai, J., Rohn, E., Patel, A. H., Morris, M. D., & Keller, E. T. (2001) · The Prostate · doi:10.1002/pros.1065 · Cited by 163

Induction of Osteoclast Differentiation by Runx2 through Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Osteoprotegerin Regulation and Partial Rescue of Osteoclastogenesis in Runx2–/– Mice by RANKL Transgene

Enomoto, H., Shiojiri, S., Hoshi, K., Furuichi, T., Fukuyama, R., Yoshida, C. A., Kanatani, N., Nakamura, R. M., Mizuno, A., Zanma, A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302457200 · Cited by 163

Cloning, Sequencing, and Functional Characterization of the Rat Homologue of Receptor Activator of NF-κB Ligand

Xu, J., Tan, J., Huang, L., Gao, X., Laird, R., Liu, D., Wysocki, S. J., & Zheng, M. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.11.2178 · Cited by 160

The Nitrogen-Containing Bisphosphonate, Zoledronic Acid, Influences RANKL Expression in Human Osteoblast-Like Cells by Activating TNF-α Converting Enzyme (TACE)

Pan, B.-Q., Farrugia, A. N., To, L. B., Findlay, D. M., Green, J., Lynch, K., & Zannettino, A. C. W. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2004.19.1.147 · Cited by 157

Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget’s disease of bone.

Menaa, C., Reddy, S. V., Kurihara, N., Maeda, H., Anderson, D., Cundy, T., Cornish, J., Singer, F. R., Bruder, J. M., & Roodman, G. D. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9133 · Cited by 154

Osteoprotegerin: Multiple partners for multiple functions

Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153

Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene

Kitazawa, R., Kitazawa, S., & Maeda, S. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00032-9 · Cited by 153

Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development

Kong, Y., Boyle, W. J., & Penninger, J. M. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00815.x · Cited by 153

RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis

Pettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R., & Gravallese, E. M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel045 · Cited by 151

Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

Mackie, P. S., Fisher, J. L., Zhou, H., & Choong, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1679 · Cited by 149

PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways

Zhang, J., Fu, M., Myles, D., Zhu, X., Du, J., Cao, X., & Chen, Y. E. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02872-7 · Cited by 150

Effectiveness of Creatine Supplementation on Aging Muscle and Bone: Focus on Falls Prevention and Inflammation

Candow, D. G., Forbes, S. C., Chilibeck, P. D., Cornish, S. M., Antonio, J., & Kreider, R. B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040488 · Cited by 149

N ew M olecules in the T umor N ecrosis F actor L igand and R eceptor S uperfamilies with I mportance for P hysiological and P athological B one R esorption

Lerner, U. H. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500202 · Cited by 147

Osteoclast-Derived Coupling Factors in Bone Remodeling

Henriksen, K., Karsdal, M. A., & Martin, T. J. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9741-7 · Cited by 146

Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis

Mizuno, A., Kanno, T., HOSHI, M., Shibata, O., Yano, K., Fujise, N., Kinosaki, M., Yamaguchi, K., Tsuda, E., Murakami, A., et al. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740200049 · Cited by 148

Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption

Sasaki, T. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10370 · Cited by 149

Root resorption and the OPG/RANKL/RANK system: a mini review

Tyrovola, J. B., Spyropoulos, M. N., Makou, M., & Perrea, D. N. (2008) · Journal of Oral Science · doi:10.2334/josnusd.50.367 · Cited by 143

Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha

Wada, N., Maeda, H., Yoshimine, Y., & Akamine, A. (2004) · Bone · doi:10.1016/j.bone.2004.04.023 · Cited by 145

Cyclic Adenosine Monophosphate/Protein Kinase A Mediates Parathyroid Hormone/Parathyroid Hormone‐Related Protein Receptor Regulation of Osteoclastogenesis and Expression of RANKL and Osteoprotegerin mRNAs by Marrow Stromal Cells

Kondo, H., Guo, J., & Bringhurst, F. R. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.9.1667 · Cited by 143

Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis

Blair, J. M., Zhou, H., Seibel, M. J., & Dunstan, C. R. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0381 · Cited by 142

RANKL/RANK—beyond bones

Hanada, R., Hanada, T., Sigl, V., Schramek, D., & Penninger, J. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0749-z · Cited by 147

Managing bone metastases and reducing skeletal related events in prostate cancer

Gartrell, B. A., & Fred Saad, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.70 · Cited by 141

Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells

Takeuchi, T., Tsuboi, T., Arai, M., & Togari, A. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00591-8 · Cited by 139

OsteoimmunologyPreprint

Okamoto, K., & Takayanagi, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031245 · Cited by 146

The pathophysiology of cancer-induced bone pain: current understanding

Urch, C. (2004) · Palliative Medicine · doi:10.1191/0269216304pm887ra · Cited by 138

Megakaryocyte-Osteoblast Interaction Revealed in Mice Deficient in Transcription Factors GATA-1 and NF-E2

Kacena, M. A., Shivdasani, R. A., Wilson, K. M., Xi, Y., Troiano, N. W., Nazarian, A., Gundberg, C. M., Bouxsein, M., Lorenzo, J. A., & Horowitz, M. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301254 · Cited by 139

A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone loss

Aoki, K., Saito, H., Itzstein, C., Ishiguro, M., Shibata, T., Blanqué, R., Mian, A. H., Takahashi, M., Suzuki, Y., Yoshimatsu, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci22513 · Cited by 136

Identification of the osteoprotegerin/receptor activator of nuclear factor‐kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis

Lu, H. ‐., Chen, Y., Chang, H., Li, C., & Kuo, M. Y. (2006) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2006.00883.x · Cited by 137

Untitled work

(2005) · PubMed · Cited by 135

IL‐23 promotes osteoclast formation by up‐regulation of receptor activator of NF‐κB (RANK) expression in myeloid precursor cells

Chen, L., Wei, X., Evans, B. A. J., Jiang, W. G., & Aeschlimann, D. P. (2008) · European Journal of Immunology · doi:10.1002/eji.200838192 · Cited by 135

OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice

Shimamura, M., Nakagami, H., Osako, M. K., Kurinami, H., Koriyama, H., Zhengda, P., Tomioka, H., Tenma, A., Wakayama, K., & Morishita, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400544111 · Cited by 134

Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases

Kikuta, J., & Ishii, M. (2012) · Rheumatology · doi:10.1093/rheumatology/kes259 · Cited by 139

Creatine supplementation in the aging population: effects on skeletal muscle, bone and brain

Gualano, B., Rawson, E. S., Candow, D. G., & Chilibeck, P. D. (2016) · Amino Acids · doi:10.1007/s00726-016-2239-7 · Cited by 133

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Dempster, D. W., Lambing, C. L., Kostenuik, P. J., & Grauer, A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.002 · Cited by 138

Effects of human aging on periodontal tissues

Huttner, E. A., Machado, D. C., de Oliveira, R. B., Antunes, A. G. F., & Hebling, E. (2009) · Special Care in Dentistry · doi:10.1111/j.1754-4505.2009.00082.x · Cited by 133

A novel molecular mechanism modulating osteoclast differentiation and function

Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S.-I., Tsuda, E., Morinaga, T., Udagawa, N., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00121-0 · Cited by 264

Osteoclast Differentiation Factor is a Ligand for Osteoprotegerin / Osteoclastogenesis-Inhibitory Factor

Shima, N., Yasuda, H., Nakagawa, N., Yamaguchi, K., Tsuda, E., Morinaga, T., Suda, T., & Higashio, K. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46869-7_43 · Cited by 1

Recent Advance in Osteoclastogenesis Inhibitory Factor.

Zhi, H. (2000) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS

16. Lack of antagonist activity of melanocyte-stimulating hormone (MSH) on the actions of IL-1 on human bone-derived osteoblast-like cells

Evans, D., Thavarajah, M., & Kanis, J. A. (1991) · Bone · doi:10.1016/8756-3282(91)90112-v

Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells

Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., Watanabe, K., & Yamada, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27091 · Cited by 299